非侵入性癌症诊断市场－依技术、设备、地区和预测的市场规模

非侵入性癌症诊断市场规模及预测

过去几年，非侵入性癌症诊断市场规模一直以中等速度增长，增长率相当高，预计在市场估计和预测期内（即 2026 年至 2032 年）将大幅增长。

大规模都市化、居民消费能力的提升、对癌症诊断最新技术进步和趋势的更多了解，以及非侵入性癌症诊断的优势，将很快推动该市场的成长。 《非侵入性癌症诊断全球市场报告》对市场进行了全面评估，全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及影响市场的关键因素。

定义全球非侵入性癌症诊断市场

非侵入性癌症诊断是使用无针诊断技术识别或测量癌症病变的过程。这种诊断方法涵盖多种技术，例如生物标记、分子生物学变化、基因结构和其他成像技术。生物技术领域的发展推动了非侵入性癌症诊断技术的发展，可用于早期发现癌症。

全球非侵入性癌症诊断市场概况

推动市场成长的主要因素是非侵入性癌症诊断，这是一种透过体内微创手术识别癌症的方法。该过程通常包含多种技术，例如基因结构识别、生物标记识别、分子生物学改造、成像技术等。全球对精准微创诊断的需求不断增长，以及医疗保健支出的不断增长，是非侵入性癌症诊断的主要驱动因素。

此外，非侵入性诊断需求的不断增长促使政府加强改善医疗基础设施，倡议计划的增加也推动了市场的发展。然而，高昂的治疗费用和严格的监管准则阻碍了市场的成长。快速的技术进步和设备创新预计将为市场带来丰厚的机会。另一方面，新兴国家尚未开发的需求也可能对市场成长构成挑战。

目录

第一章全球非侵入性癌症诊断市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球非侵入性癌症诊断市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球非侵入性癌症诊断市场（按技术）

• 概述
• 临床化学
• 免疫化学
• 分子诊断

6. 全球非侵入性癌症诊断市场（按设备）

• 概述
• 固体癌
• 血癌
• 肺癌
• 乳癌

7. 全球非侵入性癌症诊断市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

8. 全球非侵入性癌症诊断市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第九章 公司简介

• Precision Therapeutics, Inc.
• AVIVA Biosciences Corporation
• Affymetrix Inc.
• BIOVIEW Inc.
• Gen-Probe Incorporated

第十章 附录

• 相关调查

Non-Invasive Cancer Diagnosis Market Size And Forecast

Non-Invasive Cancer Diagnosis Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2026 to 2032.

Large-scale urbanization, an increase in the spending power of people, more awareness about the latest technological advancements and trends in cancer diagnosis, and the benefits of non-invasive cancer diagnosis will lead to the growth of this market shortly. The Global Non-Invasive Cancer Diagnosis Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Non-Invasive Cancer Diagnosis Market Definition

A non-Invasive cancer diagnosis is a process of identifying or measuring the cancer disease with a needle-free diagnosis technique. This diagnosis method comprises several techniques, including biomarkers, changes in molecular biology, genetic structure, and other imaging diagnosis techniques. Advancements in the biotechnology sector have enabled the development of non-invasive cancer diagnosis for the early detection of cancer.

Global Non-Invasive Cancer Diagnosis Market Overview

The primary factors driving the market growth are the non-invasive cancer diagnosis is a way to identify cancer problems with minimal incisions in the body. This process generally consists of various techniques such as gene structure identification, biomarkers, molecular biology modifications, and imaging techniques. The growing demand for accurate, minimally invasive diagnostics and growth in medical costs were observed across the globe as critical drivers.

In addition, increasing demand for non-invasive diagnostics increases government initiatives to improve medical infrastructure, and increased research and development projects drive market growth. However, high treatment costs and strict regulatory guidelines hamper market growth. Rapid technological advances and innovations in devices are expected to create beneficial opportunities for the market. On the other hand, the needs of untapped developing countries can challenge market growth.

Global Non-Invasive Cancer Diagnosis Market: Segmentation Analysis

The Global Non-Invasive Cancer Diagnosis Market is segmented on the basis of Technology, Instruments, And Geography.

Non-Invasive Cancer Diagnosis Market, By Technology

• Clinical Chemistry
• Immunochemistry
• Molecular Diagnostics

Based on Technology, The market is bifurcated into Clinical Chemistry, Immunochemistry, and Molecular Diagnostics. The Clinical Chemistry segment holds a large number of shares in the market because of the availability of the clinical data for several cancer indications and increasing non-invasive diagnostic technology, which is the factor that boosts the market growth.

Non-Invasive Cancer Diagnosis Market, By Instruments

• Solid Tumor
• Blood Cancer
• Lung Cancer
• Breast Cancer

Based on Instruments, The market is bifurcated into Solid Tumor, Blood Cancer, Lung Cancer, and Breast Cancer. The Breast Cancer segment holds a large number of shares in the market because of the increasing number of cases across the globe and enhancing healthcare sector, which is the factor that boosts the market growth.

Non-Invasive Cancer Diagnosis Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Non-Invasive Cancer Diagnosis Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The North American region holds a large number of shares in the market because of the increasing healthcare expenditure and rising research and development activities in the region. At the same time, Asia-Pacific is the fastest-growing region because of the rising number of patients with an increase in awareness regarding the minimal invasive equipment in the region, which is the factor that increased the market growth.

Key Players

The "Global Non-Invasive Cancer Diagnosis Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Precision Therapeutics Inc., AVIVA Biosciences Corporation, Affymetrix Inc., BIOVIEW Inc., Gen-Probe Incorporated, and many more. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET, BY TECHNOLOGY

• 5.1 Overview
• 5.2 Clinical Chemistry
• 5.3 Immunochemistry
• 5.4 Molecular Diagnostics

6 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET, BY INSTRUMENTS

• 6.1 Overview
• 6.2 Solid Tumor
• 6.3 Blood Cancer
• 6.4 Lung Cancer
• 6.5 Breast Cancer

7 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East And Africa

8 GLOBAL NON-INVASIVE CANCER DIAGNOSIS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Precision Therapeutics, Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 AVIVA Biosciences Corporation
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Affymetrix Inc.
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 BIOVIEW Inc.
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Gen-Probe Incorporated
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments

10 Appendix

• 10.1 Related Research